Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM -26.36% Earnings Yield (Joel Greenblatt) % is -5.08% as of Jun. 2026. The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, NovelStem International ranks worse than 66.51% on this metric.
NovelStem International's Enterprise Value for the quarter that ended in Jun. 2026 was $2.36 Mil.
NovelStem International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.12 Mil. NovelStem International's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -5.08%.
The historical rank and industry rank for NovelStem International's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NSTM'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.02 Med: 0 Max: 0
Current: -5.02
NSTM's Earnings Yield (Joel Greenblatt) % is ranked worse than 66.51% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.065
vs NSTM: -5.02
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. NovelStem International's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
NovelStem International (OTCPK:NSTM) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
NovelStem International Earnings Yield (Joel Greenblatt) % Related Terms
NovelStem International Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for NovelStem International's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International Earnings Yield (Joel Greenblatt) % Chart
For the Diagnostics & Research subindustry, NovelStem International's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NovelStem International's Earnings Yield (Joel Greenblatt) % falls into.
NovelStem International Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
NovelStem Internationals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
NovelStem International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -5.08% mean?
NovelStem International (NSTM) has a Earnings Yield (Joel Greenblatt) % of -5.08% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NovelStem International and its competitors. According to the industry distribution chart, NovelStem International ranks #141 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 66.5%.
Is NovelStem International's Earnings Yield (Joel Greenblatt) % too high?
NovelStem International's current Earnings Yield (Joel Greenblatt) % is -5.08%. Based on the distribution chart, NovelStem International ranks #141 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does NovelStem International's Earnings Yield (Joel Greenblatt) % compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #141 out of 212 companies for Earnings Yield (Joel Greenblatt) %. This places NovelStem International in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
The median Earnings Yield (Joel Greenblatt) % among Medical Diagnostics & Research companies is 0.07, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NovelStem International and its competitors. For the Medical Diagnostics & Research industry, the median Earnings Yield (Joel Greenblatt) % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current Earnings Yield (Joel Greenblatt) % is -5.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Earnings Yield (Joel Greenblatt) % of -5.08%. The current Earnings Yield (Joel Greenblatt) % is -5.08%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For NovelStem International (NSTM), the current Earnings Yield (Joel Greenblatt) % is -5.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
